<DOC>
	<DOC>NCT00548808</DOC>
	<brief_summary>The purpose of the study is to compare the insulin lispro low mixture (1, 2 or 3 daily injections) with insulin glargine (alone or with 1, 2 or 3 insulin lispro daily injections) on lowering the blood sugar level</brief_summary>
	<brief_title>A Study for Type 2 Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 2 diabetes mellitus Receiving oral antihyperglycemic medications (including metformin) without insulin injection in the last 90 days Hemoglobin A1c (HbA1c) equal to or greater than 7.0% but less than 11.0% Willing to receive insulin injection while continuing to take the prestudy oral antihyperglycemic medications Able to perform self monitoring of blood glucose Are taking any other glucoselowering agents other than metformin, sulfonylurea or Thiazolidinedione (Pioglitazone) Have taken acarbose, miglitol, pramlintide, exenatide, repaglinide, or nateglinide in the past 6 weeks, or for a total of 30 days or more, in the last 24 weeks Have a body mass index greater than 35 kg/m2 History or presence of kidney disease Have cardiac disease (Class III or IV)</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>